NON INVASIVE EVALUATION OF HEPATIC FIBROSIS IN PATIENTS WITH HEPATITIS C USING ELASTOGRAPHY

Thesis

Submitted in partial fulfillment of the requirement of M.S.c. Degree in Internal Medicine

By

Ahmed Sayed Ismail Mohamed

M.B.BCh

Supervised By

Prof. Dr. Taher El Zanaty

Professor of Internal Medicine Faculty of medicine-Cairo University

Prof. Dr. Hussein Okasha

Professor of Internal Medicine Faculty of Medicine-Cairo University

Dr. Nagwa Ramadan

Lecturer of Internal Medicine Faculty of Medicine-Cairo University

Faculty of Medicine Cairo University 2010

Abstract

HCV is a major cause of acute hepatitis and chronic liver disease, including cirrhosis and liver cancer. Globally, an estimated 170 million persons are chronically infected with HCV and 3 to 4 million persons are newly infected each year.

More than one million of people world wide die annually of hepatocellular carcinoma, the third highest cause of death due to malignant neoplasm. Hepatocellular carcinoma often develops as sequel of chronic viral hepatitis. It has been reported that the risk of hepatocellular carcinoma is related to the stage of hepatic fibrosis, making it a particularly important factor in the long term prognosis of chronic hepatitis C. The incidence of hepatocellular carcinoma increases along with progression of the stage.

The importance of histological diagnosis by liver biopsy for the assessment of the stage of hepatic fibrosis is widely acknowledged. However, due to its invasive nature, liver biopsy is limited when constant monitoring of the time course of changes in hepatic fibrosis is required, so non invasive tests may be more suitable in that context.

Key Words:

Liver cirrhosis, Hepatitis C virus, Role of liver biopsy in chronic hepatitis C, Transient elastography and other noninvasive tests to assess hepatic fibrosis in patients with viral hepatitis

Acknowledgment

First thanks to GOD

Although no words can be sufficient to show my gratitude.

I am deeply obliged and grateful to Prof. Dr. Taher El Zanaty, professor of internal medicine, faculty of medicine, Cairo University, for his valuable and continuous help, cooperation, and supervision during all the steps of this research.

I would like to express my great and sincere appreciation to Prof. Dr. Hussein Okasha, professor of internal medicine, faculty of medicine, Cairo University for his continuous interest, encouragement, great care supervision and kind advice.

I am also grateful to Dr. Nagwa Ramadan Lecturer of internal medicine, faculty of medicine, Cairo University for her patience, encouragement, supervision, the precious help and advice during preparation of this work.

I would also like to express my deep appreciation and gratefulness to Dr. Mohamed Nagieb Lecturer of internal medicine, faculty of medicine, Cairo University, and Dr. Walied Al Nabawy Lecturer of internal medicine, faculty of medicine, Bany Swaif University, for their sincere moral, help and support during the whole course of this study.

Finally I want to thank all the staff and colleagues in the department of internal medicine especially in my unit for being so nice, cooperative, and supportive to me during this study.

LIST OF CONTENTS

Title	Page No.
Introduction	خطأ! الإشارة المرجعية غير معرّفة
Aim of the work	خطأ! الإشارة المرجعية غير معرّفة
Review of Literature	
Liver cirrhosis	خطأ! الإشارة المرجعية غير معرّفة
Hepatitis C virus	خطأ! الإشارة المرجعية غير معرّفة
• Role of liver biopsy in chronic hepatitis C	خطأ! الإشارة المرجعية غير معرّفة
Transient elastography and other noninvasive tes	ts to assess
hepatic fibrosis in patients with viral hepatitis	خطأ! الإشارة المرجعية غير معرّفة
Patients and methods	خطأ! الإشارة المرجعية غير معرّفة
Results	خطأ! الإشارة المرجعية غير معرّفة
Discussion	خطأ! الإشارة المرجعية غير معرّفة
Summary	خطأ! الإشارة المرجعية غير معرّفة
References	خطأ! الإشارة المرجعية غير معرّفة
Arabic Summary	

LIST OF TABLES

Гаb. No.	Title	Page No.
Гable (1):	Clinical features of cirrhosis	خطأ! الإشارة المرجعية غير معرّف
Гable (2):	Laboratory tests and findings in cirrhosis	خطأ! الإشارة المرجعية غير معرّف
Гable (3):	Diagnostic tests in chronic liver disease, acco	
Гable (4):	Child Pugh Turcotte (CPT) classification	خطأ! الإشارة المرجعية غير معرّف
Гable (5):	Prevention and treatment for complications of	لمرجعية غير معرّفة.f cirrhosis
Гable (6):	Grading System for Recommendations	خطأ! الإشارة المرجعية غير معرّف
Table (7):	FDA Approved Qualitative Assays for DeteRNA	ection of HCV خطأ! الإشارة المرجعية غير معرّف
Table (8):	Available Assays for Quantification Serum/Plasma	of HCV in فطأ! الإشارة المرجعية غير معرّف
Sable (9):	Classification of recommendations of AAS treatment of HCV:	
able (10):	Treatment According to Stages of Chronic Ki	ية غير معرّفة.idney Diseases
able (11):	Diagnostic performance of transient ela significant fibrosis (SF) in chronic viral hepat	
able (12):	Gender and age of studied patients	خطأ! الإشارة المرجعية غير معرّف
able (13):	Laboratory data of studied patients	خطأ! الإشارة المرجعية غير معرّف
able (14):	Liver size of studied cases	خطأ! الإشارة المرجعية غير معرّف
able (15):	Liver texture of studied cases	خطأ! الإشارة المرجعية غير معرّف
able (16):	Relation between liver texture versus Elastog	ارة المرجعية غير معرّفةraphy
Table (17):	Comparison between different studie parameters among groups classified accorditexture	ing to the liver
Гable (18):	Comparison between different studied param texture	neters and liver
Table (19):	Comparison between different studied para groups classified according to the liver textur	
able (20):	Portal vein diameter in studied patients	خطأ! الإشارة المرجعية غير معرّف
Table (21):	Relation between elastography score an diameter among studied patients	
Table (22):	Splenic size of the studied cases	خطأ! الإشارة المرجعية غير معرّف
able (23):	Anterior abdominal wall diameter in studied of	

LIST OF TABLES (Cont...)

Tab. No.	Title	Page No.
Table (24):	مرجعية غير معرّفةElastography score of the studied patients.	خطأ! الإشارة ال
Table (25):	Distribution of the studied cases as regard activity stagin out of (6) according to HAI score	g خطأ! الإشارة ال
Table (26):	Relation between fibrosis stage and elastography scor among the studied group	e خطأ! الإشارة الـ
Table (27):	Correlation between elastography versus laboratory dat among the studied group	a خطأ! الإشارة ال
Table (28):	Sensitivity, specificity, positive predictive value (PPV negative predictive value (NPV), and diagnostic accurac among group I (fibrosis score 0, 1, 2), group II (fibrosis score 3, 4) and group III (fibrosis score 5, 6).	y
Table (29):	Relation between anterior abdominal wall diameter an elastography.	
Table (30):	The accuracy of elastography score in relation to live texture	
Table (31)	Summarizes the sensitivity, specificity, PPV and NP among of the previously mentioned paper مرجعية غير معرّفة	

LIST OF FIGURES

Fig. No.	Title	Page No.
Figure (1):	Vascular and architectural alterations in cirrhosis. Mesenteric blood flows via the portal vein and hepatic artery that extend branches into terminal portal tracts.	الإشارة المرجعية غير معرّ
Figure (2):	Hepatitis C virus (HCV): Model structure and genome organization	خطأ! الإشارة المرج
Figure (3):	Demonstrates the behavior of hard and soft tissue when compressed.	خطأ! الإشارة المرج
Figure (4):	The strain image is estimated by calculating the gradient of the displacements and is displayed as a color overlay of the B-mode image	خطأ! الإشارة المرج
Figure (5):	ر معرّفة. Hitachi Real-time Tissue Elastography (HI-RTE)	خطأ! الإشارة المرجعية غير
Figure (6):	Proposed algorithm combining transient elastography and serum indices for the first-line noninvasive assessment of hepatic fibrosis in patients with chronic viral hepatitis	خطأ! الإشارة المرج
Figure (7):	عية غير معرّفة.	خطأ! الإشارة المرج
Figure (8):	عية غير معرّفة.	خطأ! الإشارة المرج
Figure (9):	عية غير معرّفة.	خطأ! الإشارة المرج
Figure (10):	Relation between liver texture versus Elastography.	طأ! الإشارة المرجعية غير ا
Figure (11):	عية غير معرّفة	خطأ! الإشارة المرج
Figure (12):	Relation between elastography score and portal vein diameter among studied patients	خطأ! الإشارة المرج
Figure (13):	عية غير معرّفة	خطأ! الإشارة المرج
Figure (14):	Distribution of the studied cases as regard anterior abdominal wall diameter	خطأ! الإشارة المرج
Figure (15):	عية غير معرّفةElastography score of the studied patients	خطأ! الإشارة المرج
Figure (16):	Distribution of the studied cases as regard activity staging out of (6)	خطأ! الإشارة المرج
Figure (17):	Relation between fibrosis stage and elastography among the studied group	خطأ! الإشارة المرج
Figure (18):	Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) among group I (fibrosis score 0, 1, 2), group II (fibrosis score 3, 4) and group III (fibrosis score 5, 6)	خطأ! الإشارة المرج

LIST OF ABBREVIATIONS

Abbrev.	Meaning
+LR	Positive likelihood ratio
γ-GT	Gamma-glutamyl transpeptidase
μg	Microgram
2 hr PP	2 hours Post Prandial
AASLD	American Association for the Study of Liver Diseases
ALP	Alkaline phosphatase
ALT	Alanine aminotransferase
AMA	Antimitochondrial antibodies
APRI	AST Platelet Ratio Index
AST	Aspartate aminotransferase
ATP	Adenosine triphosphate
AUROC	Area Under the Receiver Operating Characteristic Curve
CA	California
Ca	California
CBC	Complete blood count
CD	Cluster designation
CDT	Carbohydrate Deficient Transferrin
CHC	Commonwealth Health Corporation
CI	Confidence interval
CIA	Chemiluminescence immunoassay
CLD	Chronic liver disease
CNS	Central Nervous System
\mathbf{CPT}	Child-Pugh-Turcotte
\mathbf{CT}	Computerized Tomography
CTP	Child-Turcotte-Pugh
D.Bil	Direct Bilirubinaemia
DANA	Dynamic Actor Network analysis
DDW	Digestive Diseases Week
dL	Decilitre
DNA	Deoxyribonucleic Acid
dsRNA	Double-stranded RNA
e.g.	for example
ECM	Extracellular matrix
EIA	Enzyme immunoassay
ELF	Enhanced Liver Fibrosis
ELISA	Enzyme-linked immunosorbent assay
et al	et alii = and others
ETR	End of treatment response
EVR	Early virologic response
F	Fibrosis
FBS	Fasting Blood Sugar
FDA	Food and Drug Administration
G-CSF	Granulocyte colony stimulating factor

LIST OF ABBREVIATIONS (Cont...)

A1.1	26
Abbrev.	Meaning
GFR	Glomerular Filtration Rate
GGT	Gamma-glutamyl transpeptidase
h	Hours
HAART	Highly active antiretroviral therapy
HAI	Histology activity index
HAS	Haute Autorite´ de Sante´
HAV	Hepatitis A virus
HBcAb	Hepatitis B core Antibody
\mathbf{HBeAg}	Hepatitis B envelope Antigen
HBsAg	Hepatitis B surface Antigen
HBV	Hepatitis B virus
HCC	Hepatocellular carcinoma
HCV	The hepatitis C virus
HCV-LT	HCV liver transplant patients
HI-RTE	Hitachi Real-time Tissue Elastography
HIV	Human immunodeficiency virus
HS	Highly significant
i.e.	id est = that it
IASL	International Association for the Study of the Liver
IFN	Interferon
$IFN\alpha$	Interferon Alpha
$IFN\gamma$	Type II interferon
\mathbf{IL}	Interleukin
IMPDH	Inosine monophosphate dehydrogenase
INNO	Innogenetics
INR	International normalised ratio
iQur Ltd	UK pathology services in Southampton
IRES	Internal ribosome entry site
IRES	Internal ribosome entry site
ISIS	International School of Information Science
IU	International Unit
IU	International Units
KDIGO	Kidney Disease: Improving Global Outcomes
kg	Kilogram
kPa	Kilopascals
L	Liter
LB	Liver biopsy
LhRNAs	Long hairpin RNAs
LiPa L:D-	Line probe assay
LiPa	Chapter of HCV, P10
LKM	Liver Kidney Microsomal

LIST OF ABBREVIATIONS (Cont...)

Abbrev.	Meaning
-LR	Negative likelihood ratio
MELD	Model for End Stage Liver Disease
mEq	<u>milliequivalent</u>
mg	Milligram
miRNA	MicroRNA
MIU	Millie International Unit
mL	Milliliter
mm	Millimeter
MMPD	merimepodib
\mathbf{MR}	Magnetic resonance
MRI	Magnetic Resonance Imaging
mRNA	Messenger Ribonucleic acid
NANB PTH	non-A, non-B post-transfusion hepatitis
NC	North Carolina
NC	North Carolina
NIH	National Institutes of Health
NJ	New Jersey
NM283	Valopicitabine also known as NM283 is a
	nucleosidepolymerase inhibitor.
NPV	Negative predictive value
NS	Non significant
NS protease	Nonstructural protease
NTR	Chap HCV, P54
NY	New York
P value	Predictive value
pANCA	Perinuclear Anti-Neutrophil Cytoplasmic Antibody
PC	Prothrombin Concentration
PCR	Polymerase chain reaction
PEG-IFN	Pegylated Interferon
PI	Protease inhibitor
PPV	Positive predictive value
PT	Prothrombin Time
RBCs	Red blood cells
RBV	Ribavirin
RIBA	Recombinant immunoblot assay
RNA	Ribonucleic acid
RNAi	RNA interference
ROC	Receiver-operating characteristics
ROI	Region of interest
RT	Real-Time
RVR	Rapid Virological Response

LIST OF ABBREVIATIONS (Cont...)

Abbrev.	Meaning
\mathbf{S}	Significant
SD	Standard Deviation
SF	Significant fibrosis
SIA	Strip Immunoblot Assay
siRNA	Small interfering RNA
SLA antibodies	Soluble Liver Antibody
SOD	Superoxide dismutase
SP	Specificity
STAT	Specifically targeted antiviral therapy
STAT-C	Specifically targeted antiviral therapy drugs for HCV
SVR	Sustained virological response
SVR	Virological response rate
T.Bil	Total Bilirubinaemia
TE	Transient elastography
THV	Terminal Hepatic Vein
TIPS	Transjugular Intrahepatic Portosystemic Shunt
TLR	Toll-like receptor
TMA	Transcription-mediated amplification
TPV	Terminal Portal Vein
U.S.	United States
UK	United Kingdom
ULN	Upper limit of normal
USA	United States of America
VX	Vertex Pharmaceuticals Telaprevir
X	The numerical average of a set of data is called \mathbf{x} -bar

INTRODUCTION

HCV is a major cause of acute hepatitis and chronic liver disease, including cirrhosis and liver cancer. Globally, an estimated 170 million persons are chronically infected with HCV and 3 to 4 million persons are newly infected each year. HCV is spread primarily by direct contact with human blood. The major causes of HCV infection worldwide are use of unscreened blood transfusions, and re-use of needles and syringes that have not been adequately sterilized (*Chapman et al., 2006*).

More than one million of people world wide die annually of hepatocellular carcinoma, the third highest cause of death due to malignant neoplasm. Hepatocellular carcinoma often develops as sequel of chronic viral hepatitis. It has been reported that the risk of hepatocellular carcinoma is related to the stage of hepatic fibrosis, making it a particularly important factor in the long term prognosis of chronic hepatitis C. The incidence of hepatocellular carcinoma increases along with progression of the stage (*Shiratori et al.*, 2000).

The importance of histological diagnosis by liver biopsy for the assessment of the stage of hepatic fibrosis is widely acknowledged. However, due to its invasive nature, liver biopsy is limited when constant monitoring of the time course of changes in hepatic fibrosis is required, and non invasive tests should be performed as well (*Ishak et al.*, 1995). Abdominal ultrasonography is the most useful non invasive diagnostic technique for the assessment of chronic hepatitis. However, for the assessment of staging in border line cases, ordinary ultrasonography is limited because images can change very slightly due to differences in the resolving power and image settings in the equipment used (*Fujimoto et al.*, 2008).

Elastography uses the combined autocorrelation method to rapidly calculate the relative hardness of tissue from the degree of tissue distortion, and display this information as real-time, color images (*Fujimoto et al.*, 2008).

The non invasive assessment was possible with Elastography, with the obtained liver elasticity score becoming significantly higher as the staging increased, satisfactorily reflecting the degree of fibrosis (*Fujimoto et al.*, 2008).

AIM OF THE WORK

To investigate the usefulness of Elastography for the evaluation of hepatic fibrosis in patients with HCV, as an alternative modality to liver biopsy.